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Olivier Garraud1,2* and James Li3During the last decade, microbial science was one of the
hottest topics in scientific research with the number of
publications in this field nearly doubling every 5 years.
The results of these studies help to bring us the develop-
ment of hundreds of vaccines and drugs for human and
veterinary use. The results of our research not only pro-
tect humans they also help to provide stable food supply
to our community. Meanwhile, we have been continu-
ously—and we still are—under threat from new emer-
ging infections such as avian influenza, new seasonal flu,
SARS and recently the Ebola virus; Dengue virus infec-
tion is forecasted to develop worldwide, posing novel
threats. In addition, other pathogenic microbes such as
HIV, Mycobacterium tuberculosis, and antibiotic resist-
ant bacteria that are widespread in parts of our popula-
tion further threaten our safety. Currently, scientists and
clinicians are working closely together to develop new
treatments to fight against these infections; however,
questions are continuously raised to understand how the
immune system that happens to be defeated by a num-
ber of dangerous pathogens can be manipulated to com-
bat such infections.
Our immune system is indeed designed to protect us
from invaders.
– Innate immunity is the first line of defense against
infection. There have been amazing discoveries in
the field of innate immunity, with lots of newly
discovered cells or cell subsets that have a crucial
function but innate immunity alone is not enough
for us to get rid of infections. More precisely, we
still do not fully understand how these pathogens
activate our immune system and how our immune
system fights against pathogens. After the early
innate immune responses, the body develops the* Correspondence: ogarraud@ints.fr
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infections.
– Our knowledge on adaptive immunity is also
limited, especially on the generation of antibodies.
Furthermore, the genetics of antigen presentation
and genetic susceptibility to infections appear
seminal, but are not fully comprehended.
– The study of intracellular parasites and
mycobacteria helped open the door to modern
immunology back in the 90’s, leading to the
discovery of functionally distinct helper T cell
subpopulations Th0, Th1, Th2. Furthermore, we have
recently discovered more immune cell subsets
including ThFH, Th9, Th17, TRegs, along with the non-T
lymphocyte effectors and regulators. However, the
fight against both types of infectious pathogens
(intracellular parasites and mycobacteria) has
poorly benefited from the tremendous progress
made in immunology. We are no closer to containing
the spread of these pathogens in our community, as
we are still far from limitation and even more far from
eradication. Our modern immunology knowledge has
helped us to graft kidneys, hearts and lungs, livers,
intestines, and even hands and faces, but we still fail in
combating the major five killers regarding infectious
diseases i.e. lower respiratory infections, diarrheal
diseases, HIV/AIDS, tuberculosis and malaria.
Although these diseases are usually found in developing
countries, we also need to pay more attention, just like
the Ebola pandemic, as it can easily spread and become
a global problem if not properly dealt with.
– Vaccines are our ultimate weapons against microbial
infection. However, in spite of all our efforts in
vaccine development and more than 120 years after
the first human vaccine against the rabies virus,
there are still some very disappointing failures in the
development of efficient vaccines against some
major infectious killers and debilitating pathogens.
In 1967, one of the leading journals, Nature
(London), claimed the discovery of a vaccine againstThis is an Open Access article distributed under the terms of the Creative
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vaccine has still not been approved for human use.
Another famous example is the development of the
HIV vaccine. Since 1983, scientists and clinicians
have investigated the treatment of AIDS. After years
of effort, different anti-viral drugs and regimes have
been successfully developed in order to control
AIDS progression. However, although a huge
amount of funding has been spent, the progress of
the development of a successful HIV vaccine is still
lagging far behind public expectations. Apart from
vaccine development for newly identified microbes,
there are also difficulties faced in developing improved
vaccines against some pathogens. Tuberculosis is a
disease caused by M. tuberculosis. A hundred years ago,
BCG was developed as the vaccine for tuberculosis.
Due to its limited efficacy on the protection against
tuberculosis, there is high expectancy that a suitable
vaccine would replace the canonical BCG vaccine.
Despite its extremely debated shortfalls, the BCG
vaccine is still widely used in many healthcare systems
to combat the spread of tuberculosis and leprosy,
which is another complication that has suffered from a
lack of both efficient therapeutic and preventive means
against mycobacterium infection.
– Due to a number of unsuccessful vaccine design
trials targeting major epitopes of infectious agents,
scientists are starting to develop other strategies to
defend the host. The current trend on vaccine
design and adjuvant development is to either
activate the host immune system to fight against
pathogens or to exhaust specific as well as
non-specific immune responses to dampen
diseases, such as autoimmune diseases and cancer.
In addition, there are several vaccines undergoing
clinical trials that are targeting both the pathogens
themselves and also boosting the immune response
specific to an infection. Autoimmune disorders and
cancer would not be expected to be questioned in
this “series” dedicated to “Infection and Immunity”;
however, novel findings in immunology re-
emphasizes on the role of infectious triggers, acute
and then chronic inflammation, and chronic state
pathogenesis and immune impairment: a look back
to latent infection and how it affects early immune
responses may give new directions for future care
and cure of patients.
– Another puzzling issue in the world currently is the
incredible increase of patients with mild or severe
allergic-type symptoms. Allergy affects billions of
people worldwide and can be life threatening.
Allergy can be caused by numerous environmental
factors such as air pollution and various chemical;
participation of infectious triggers—present orabsent—is still debated in the constitution of atopic
states (the hygiene theory): this demonstrates that
our immune system may have to be trained (in
particular to face microbes, that are pathogen or
not) in order to gain optimal performance; this also
calls for a revisit of the pathogenicity of microbes
and—at large—of the role of the microbial ecology
of the human being(s), to maintain a certain
equilibrium and avoid emergent infectious outbreaks.
– Lastly, because this is a fast expanding universe—
though linked to the above mentioned item relative
to microbial ecology—, more research should also
be focused on the precise role of novel immune
organs such as the microbiota, which is envisioned
to dialog with the environment; this is expected to
allow a revisit of inflammatory bowel diseases and
treatment regimens, that may now start with viral
(CMV) cure prior to immunomodulating agents.
This series of forum articles in “BMC Immunology” is
thus aimed at addressing debatable questions in the field
of infection and immunity, with the hope of promoting
research to further our understanding of the compli-
cated immune system and ultimately, to provide benefits
to humans while not altering their ecology.
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